These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 21397482

  • 1. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW, Mahler DA, Gale R, Owen R, Kramer B.
    Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
    [Abstract] [Full Text] [Related]

  • 2. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
    Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.
    COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
    [Abstract] [Full Text] [Related]

  • 4. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M, Rossi A, Lawrence D, McBryan D.
    Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 6. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B, INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.
    Eur Respir J; 2011 Feb; 37(2):273-9. PubMed ID: 20693243
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
    Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP.
    Value Health; 2012 May; 15(3):524-33. PubMed ID: 22583463
    [Abstract] [Full Text] [Related]

  • 8. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun 15; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
    Cope S, Zhang J, Williams J, Jansen JP.
    BMC Pulm Med; 2012 Jun 25; 12():29. PubMed ID: 22732017
    [Abstract] [Full Text] [Related]

  • 11. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B.
    Respir Med; 2012 Dec 25; 106(12):1715-21. PubMed ID: 23040786
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb 25; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
    Mahler DA, Buhl R, Lawrence D, McBryan D.
    Pulm Pharmacol Ther; 2013 Jun 25; 26(3):348-55. PubMed ID: 23434446
    [Abstract] [Full Text] [Related]

  • 14. [Indacaterol--a new hope for maximising bronchodilation?].
    Mihălţan F.
    Pneumologia; 2011 Jun 25; 60(1):21-5. PubMed ID: 21548196
    [Abstract] [Full Text] [Related]

  • 15. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
    Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B, INTENSITY study investigators.
    Eur Respir J; 2011 Oct 25; 38(4):797-803. PubMed ID: 21622587
    [Abstract] [Full Text] [Related]

  • 16. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
    Kerstjens HA, Deslée G, Dahl R, Donohue JF, Young D, Lawrence D, Kornmann O.
    Pulm Pharmacol Ther; 2015 Jun 25; 32():101-8. PubMed ID: 25743376
    [Abstract] [Full Text] [Related]

  • 17. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM, Wagner F, Khindri S, Drollmann AF.
    COPD; 2011 Oct 25; 8(5):340-5. PubMed ID: 21793716
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
    Girodet PO, Jasnot JY, Le Gros V, Decuypère L, Cao W, Devouassoux G.
    Respir Med; 2017 Jul 25; 128():92-101. PubMed ID: 28566230
    [Abstract] [Full Text] [Related]

  • 19. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 25; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 20. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA, Buhl R, Lawrence D, Young D.
    Respir Med; 2015 Jan 25; 109(1):105-11. PubMed ID: 25433954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.